GMED Stock Recent News
GMED LATEST HEADLINES
Globus Medical debuts DuraPro with Excelsius integration, boosting its Power Portfolio.
AUDUBON, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its next-generation oscillating system, DuraPro™, as the latest addition to the Power Portfolio, designed to advance procedural workflows through safety features and efficiency.
Globus Medical shares have reset after a soft Q1 and Nevro acquisition, making valuations more attractive despite near-term dilution. The company's strong growth, driven by NuVasive integration and product launches, is offset by margin compression and recent earnings guidance cuts. A $500M buyback, net cash position, and sales multiples below 3x provide downside support and renewed appeal after a 25-30% share price pullback.
NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE:GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE:GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.